Back to Journals » Therapeutics and Clinical Risk Management » Volume 9

An update of teriflunomide for treatment of multiple sclerosis

Authors Oh J, O'Connor PW

Received 1 November 2012

Accepted for publication 11 December 2012

Published 26 April 2013 Volume 2013:9 Pages 177—190

DOI https://doi.org/10.2147/TCRM.S30947

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Jiwon Oh,1,2 Paul W O’Connor2

1Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; 2Division of Neurology, St Michael’s Hospital, Toronto, ON, Canada

Abstract: There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review will summarize teriflunomide's historical development, clinical pharmacology, studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context of existing treatment options.

Keywords: teriflunomide, multiple sclerosis, clinical trials, review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]